Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitorsJörge E. Cortes, Dan Jones, Elias Jabbour et al.|Blood|2007Cited by 298
Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai–Dorfman diseaseSofía Garcés, C. Cameron Yin|Modern Pathology|2017Cited by 292
Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patientsSanam Loghavi, Joseph D. Khoury, Shimin Hu et al.|Journal of Hematology & Oncology|2015Cited by 139
<i><scp>MYC</scp>/<scp>BCL</scp>6</i> double‐hit lymphoma (<scp>DHL</scp>): a tumour associated with an aggressive clinical course and poor prognosisShaoying Li, L. Jeffrey Medeiros, Parth Desai et al.|Histopathology|2015Cited by 106
Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (<scp>MCL</scp>) ‐ outcomes and mutation profile from venetoclax resistant <scp>MCL</scp> patientsShuangtao Zhao, Preetesh Jain, Rashmi Kanagal‐Shamanna et al.|American Journal of Hematology|2020Cited by 84